FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding

  1. Wei Hu
  2. Yong Zhang
  3. Xiaolin Sun
  4. Tongtong Zhang
  5. Liling Xu
  6. Hengyi Xie
  7. Zhanguo Li
  8. Wanli Liu  Is a corresponding author
  9. Jizhong Lou  Is a corresponding author
  10. Wei Chen  Is a corresponding author
  1. Zhejiang University School of Medicine, China
  2. Institute of Biophysics, Chinese Academy of Sciences, China
  3. Peking University People's Hospital, China
  4. Tsinghua University, China

Abstract

FcγRIIB binding to its ligand suppresses immune cell activation. A single-nucleotide polymorphic (SNP) change, I232T, in the transmembrane (TM) domain of FcγRIIB loses its suppressive function, which is clinically associated with systemic lupus erythematosus (SLE). Previously, we reported that I232T tilted FcγRIIB's TM domain. In this study, combining with molecular dynamics simulations and single-cell FRET assay, we further reveal that such tilting by I232T unexpectedly bends the FcγRIIB's ectodomain towards plasma membrane to allosterically impede FcγRIIB's ligand association. I232T substitution reduces in-situ two-dimensional binding affinities and association rates of FcγRIIB to interact with its ligands, IgG1, IgG2 and IgG3 by three to four folds. This allosteric regulation by a SNP provides an intrinsic molecular mechanism for the functional loss of FcγRIIB-I232T in SLE patients.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Wei Hu

    Department of Neurobiology, Institute of Neuroscience, Zhejiang University School of Medicine, Zhejiang, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Yong Zhang

    CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Xiaolin Sun

    Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Tongtong Zhang

    Department of Neurobiology, Institute of Neuroscience, Zhejiang University School of Medicine, Zhejiang, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Liling Xu

    Institute for Immunology, Tsinghua University, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Hengyi Xie

    Institute for Immunology, Tsinghua University, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Zhanguo Li

    Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Wanli Liu

    School of Life Sciences, Tsinghua University, Beijing, China
    For correspondence
    liulab@tsinghua.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0395-2800
  9. Jizhong Lou

    CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
    For correspondence
    jlou@ibp.ac.cn
    Competing interests
    The authors declare that no competing interests exist.
  10. Wei Chen

    Department of Neurobiology, Institute of Neuroscience, Zhejiang University School of Medicine, Zhejiang, China
    For correspondence
    jackweichen@zju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5366-7253

Funding

Natural Basic Research Program of China (2015CB910800)

  • Wei Chen

Natural Science Foundation of China (31470900)

  • Wei Chen

Natural Science Foundation of China (31522021)

  • Wei Chen

Natural Science Foundation of China (11672317)

  • Jizhong Lou

Natural Science Foundation of China (11772348)

  • Yong Zhang

Fundamental Research Founds for the Central Universities (2015XZZX004-32)

  • Wei Chen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The ethics committee of Peking University People's Hospital approved this study and informed consents were obtained from each patient and healthy volunteer. All the human cell associated experimental guidelines were approved by the Medical Ethics Committee of Peking University People's Hospital (approval no. 2014PHB116-01) and by the Medical Ethics Committee of Tsinghua University (approval no. 20180029).

Copyright

© 2019, Hu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,605
    views
  • 290
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Wei Hu
  2. Yong Zhang
  3. Xiaolin Sun
  4. Tongtong Zhang
  5. Liling Xu
  6. Hengyi Xie
  7. Zhanguo Li
  8. Wanli Liu
  9. Jizhong Lou
  10. Wei Chen
(2019)
FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding
eLife 8:e46689.
https://doi.org/10.7554/eLife.46689

Share this article

https://doi.org/10.7554/eLife.46689

Further reading

    1. Immunology and Inflammation
    Hong Yu, Hiroshi Nishio ... Drew Pardoll
    Research Article

    The adaptive T cell response is accompanied by continuous rewiring of the T cell’s electric and metabolic state. Ion channels and nutrient transporters integrate bioelectric and biochemical signals from the environment, setting cellular electric and metabolic states. Divergent electric and metabolic states contribute to T cell immunity or tolerance. Here, we report in mice that neuritin (Nrn1) contributes to tolerance development by modulating regulatory and effector T cell function. Nrn1 expression in regulatory T cells promotes its expansion and suppression function, while expression in the T effector cell dampens its inflammatory response. Nrn1 deficiency in mice causes dysregulation of ion channel and nutrient transporter expression in Treg and effector T cells, resulting in divergent metabolic outcomes and impacting autoimmune disease progression and recovery. These findings identify a novel immune function of the neurotrophic factor Nrn1 in regulating the T cell metabolic state in a cell context-dependent manner and modulating the outcome of an immune response.

    1. Immunology and Inflammation
    Takashi Watanabe, Hikaru Hata ... Hidehiro Fukuyama
    Research Article

    Antibodies are powerful tools for the therapy and diagnosis of various diseases. In addition to conventional hybridoma-based screening, recombinant antibody-based screening has become a common choice; however, its application is hampered by two factors: (1) screening starts after Ig gene cloning and recombinant antibody production only, and (2) the antibody is composed of paired chains, heavy and light, commonly expressed by two independent expression vectors. Here, we introduce a method for the rapid screening of recombinant monoclonal antibodies by establishing a Golden Gate-based dual-expression vector and in-vivo expression of membrane-bound antibodies. Using this system, we demonstrate the rapid isolation of influenza cross-reactive antibodies with high affinity from immunized mice within 7 days. This system is particularly useful for isolating therapeutic or diagnostic antibodies, for example during foreseen pandemics.